Eterna Therapeutics Announces $9.2M Convertible Debt And Warrant Financing
Eterna Therapeutics Announces $9.2M Convertible Debt And Warrant Financing
Eterna Therapeutics Inc. a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the execution of a securities purchase agreement with accredited investors for the sale of approximately $9.2 million aggregate principal amount of senior convertible promissory notes and accompanying warrants to purchase an aggregate of 9,579,014 shares of common stock in a private placement transaction that was priced at-the-market under Nasdaq rules. The Company expects to hold an initial closing at which it expects to receive proceeds of approximately $7.8 million on December 15, 2023 and the remainder at a closing to occur no later than January 15, 2023.
致力于发掘mRNA细胞工程为患者提供变革性新药的潜力的生命科学公司Eterna Therapeutics Inc. 今天宣布与合格投资者签订证券购买协议，出售本金总额约920万美元的优先可转换期票和随附的认股权证，通过根据纳斯达克规则在市场上定价的私募交易中购买总计9,579,014股普通股。该公司预计将在2023年12月15日举行首次收盘，预计将在2023年12月15日收到约780万美元的收益，其余款项将在不迟于2023年1月15日收盘时收到。
